Lucentis biosimilar Ximluci approved in UK

17 January 2023

Adding to European Commission clearance in November last year, German drugmaker STADA Arzneimittel (SAZ: Xetra) and Sweden’s Xbrane Biopharma (Nasdaq Stockholm: XBRANE) announced that their Ximluci (ranibizumab), a biosimilar referencing Lucentis, has been granted marketing authorization by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

STADA, which gained rights to market the drug in Europe and other territories from Xbrane in 2018, is preparing to launch Ximluci in the UK during 2023. Xbrane’s share rose 8.3% to 87.60 kronor on the news, while STADA was unchanged.

Indicated for the treatment of various ophthalmic conditions such as neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), Lucentis is marketed by Roche (ROG: SIX) in the USA and Swiss rival Novartis (NOVN: V) elsewhere.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK